Amgen reports fiscal Q3 2025 results: revenue $9.56B, up 12% from a year earlier

Amgen filed a Form 8-K with the SEC on Nov 4, 2025, 4:04 PM ET, reporting an event dated Nov 4, 2025. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q3 2025 (quarter ended Sep 30, 2025); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $9.56B (+12.4% from $8.50B a year earlier)
• Operating income: $2.53B (+23.4% from $2.05B a year earlier)
• Net income: $3.22B (+13.6% from $2.83B a year earlier)
• Diluted EPS: $5.93 (+13.6% from $5.22 a year earlier)
• Form 8-K accepted by EDGAR Nov 4, 2025, 4:04 PM ET
• Accession number 0000318154-25-000070

SEC filing 8-K · accession 0000318154-25-000070 · sec.gov ↗